Quick Facts

• Therapeutic Domain: Assists in managing high blood sugar levels associated with Type 2 diabetes mellitus in adults.
• Primary Use Condition: Indicated when diet, physical activity, and weight management efforts alone are not sufficient to support blood glucose control.
• Mechanism: Functions to support the regulation of blood glucose as part of a comprehensive management plan.

---

What Gliclada 60 mg Treats: Main Uses and Benefits

Gliclada 60 mg is an approved prescription medication used to assist adults with Type 2 diabetes mellitus in managing their condition. It is used as an additional tool for supporting appropriate blood glucose levels when recommended non-pharmacological interventions—such as following dietary recommendations, increasing physical exercise, and pursuing weight reduction—do not adequately address elevated blood sugar.

This medication is a component of a larger therapeutic regimen. Its primary role is to help reduce hyperglycemia, which refers to high blood sugar. Maintaining blood glucose within a target range is necessary to manage Type 2 diabetes and may help prevent health complications associated with the condition over time. The medication is intended for the long-term management of this chronic metabolic condition.

Gliclada 60 mg, containing the active substance gliclazide, is an oral antidiabetic medicine used for the treatment of Type 2 diabetes mellitus in adults. It is typically prescribed when diet, regular physical exercise, and weight reduction alone are insufficient to maintain adequate blood sugar control.

---

Who Cannot Use Gliclada 60 mg?

The use of Gliclada is contraindicated in several specific situations to prevent serious complications. You must not take this medicine if you have:

• Type 1 diabetes (insulin-dependent diabetes).
• Diabetic ketoacidosis (ketone bodies and sugar in your urine), pre-coma, or diabetic coma.
• Severe kidney (renal) or liver (hepatic) impairment.
• A known hypersensitivity or allergy to gliclazide, any other sulfonylurea medications, sulfonamides, or any of the other ingredients in the tablet.
• Are currently being treated with miconazole (a medicine for fungal infections) via systemic route or oromucosal gel.
• Are breastfeeding. Its use is generally not recommended during pregnancy and should be avoided.

---

Special Considerations for Use
Use with caution in patients who are malnourished, elderly, or have certain endocrine disorders (e.g., severe thyroid, pituitary, or adrenal insufficiency), as these conditions can increase the risk of hypoglycemia (low blood sugar).
The tablet also contains lactose, making it unsuitable for individuals with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

Interactions with other medicines and products

The interaction profile for Gliclada 60 mg (Gliclazide) is defined by officially documented patterns that either potentiate its blood glucose-lowering action or alter its concentration in the bloodstream.

Formal Interaction Restrictions

Co-administration with systemic Miconazole (including oral gel formulations) is strictly contraindicated, as this combination is documented to lead to a severe increase in the hypoglycaemic effect. The consumption of alcohol (ethanol) is not recommended because it may potentiate the blood sugar reduction and carries a risk of a disulfiram-like reaction.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type	Interacting Substances/Classes	Outcome and Mechanism Basis
Pharmacodynamic Potentiation	Other Antidiabetic Agents (e.g., insulin, metformin, DPP-4 inhibitors), ACE Inhibitors, Non-selective Beta-blockers	Additive blood glucose lowering effect, increasing the risk of hypoglycemia.
Exposure Increase (PK)	CYP2C9 Inhibitors (e.g., Fluconazole, Phenylbutazone)	Formal increase in Gliclazide plasma concentrations, raising the risk of severe hypoglycemia.
Exposure Decrease (PK)	CYP2C9 Inducers (e.g., Rifampicin), St. John's Wort	Formal reduction in Gliclazide plasma concentrations due to enzyme induction, which may reduce its efficacy.

No specific mandatory administration timing rules requiring separation by a set number of hours are listed in major regulatory prescribing information.

Gliclada 60 mg contains gliclazide, a modified-release medication that acts primarily through multiple mechanisms to influence glucose homeostasis.

Modulation of Pancreatic beta-Cell Signaling

Gliclazide selectively targets the sulfonylurea receptor 1 (SUR1) on pancreatic beta-cells. This binding action closes the ATP-sensitive potassium (K ATP ) channels in the cell membrane. The resulting decrease in potassium efflux causes the beta-cell to depolarize, which in turn opens voltage-gated calcium channels. This increase in intracellular calcium ions triggers the exocytosis of stored insulin from the beta-cells.

---

Enhancement of Peripheral Tissue Sensitivity

Beyond its primary action on the pancreas, gliclazide has demonstrated extrapancreatic effects. These effects include potentiating insulin action on peripheral tissues. This mechanism influences peripheral insulin sensitivity, facilitating the uptake of glucose by peripheral tissues and increasing systemic glucose disposal.

---

Anti-Aggregatory and Vascular Mechanisms

Gliclazide engages mechanisms that extend beyond pancreatic action, including an influence on platelets and the vascular endothelium. It has been shown to reduce platelet adhesion and aggregation and may enhance fibrinolytic activity. This modulatory effect influences hemostasis by modifying processes within targeted vascular pathways.

Instruction Map: How to use Gliclada 60 mg — Administration Guidelines

This section outlines the standardized protocol for the administration and dosage of Gliclada 60 mg Modified-Release (MR) tablets.

---

Administration Scope

Category	Instruction
Route of administration:	Oral use (swallowed).
Dosing schedule:	Initial Dose: 30 mg daily. Maintenance Range: 30 mg to 120 mg daily. Maximum Daily Dose: 120 mg.
Timing in relation to meals:	Must be taken as a single intake at breakfast time with regular food consumption.
Preparation requirements:	The 60 mg tablet is scored and may be divided to obtain a 30 mg dose.
Age-group administration rules:	Older Adults (ge 65): Use the same 30 mg initial dose. Pediatrics: Safety and efficacy are not established.
Missed-dose rules:	If a dose is forgotten, it must be skipped; the subsequent dose must not be increased to compensate.
Special procedural conditions:	The MR tablet must be swallowed whole with water and must not be crushed or chewed to preserve its modified-release properties.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type:	Oral.
Frequency pattern:	Once daily (QD).
Use-context constraints:	Fixed time-of-day (breakfast) and fixed form (swallow whole) constraints.

---

Resulting Procedural Structure

Step sequence:

• Take the dose as a single intake once daily.
• Swallow the Modified-Release tablet whole with a drink of water at breakfast time.
• Dose adjustments are made in 30 mg increments at intervals of at least one month, guided by the patient's metabolic response.

Connection to the overall use protocol (2–4 sentences): The administration follows a structured protocol centered on once-daily oral administration at a precise time (breakfast) to facilitate the modified-release delivery of the active compound. This framework governs the dose range, the titration schedule, and the specific procedure for tablet handling, defining the standard use pattern.

Research Evidence / Overview of Studies for Gliclada 60 mg

---

Evidence Supporting Use in Type 2 Diabetes Mellitus

The research into Gliclada 60 mg has been anchored by a variety of study types, primarily including Randomized Controlled Trials (RCTs). These RCTs are often synthesized through systematic reviews and meta-analyses, which are methods used to combine and summarize the findings of multiple individual trials. This type of research was applied in studies examining the drug's role in the assessment of high blood sugar associated with Type 2 diabetes for adults whose condition is not sufficiently managed by changes in diet and exercise alone.

The research involved observation when the drug was studied on its own (monotherapy) and when studied alongside other established oral antidiabetic treatments (combination therapy). Research evaluated the long-term glucose biomarker, Glycated Hemoglobin (HbA1c). Research examined patterns in these measured biomarkers when the drug was observed against placebo or other treatments.

---

Outcomes Examined in Clinical Trials

Studies primarily monitored outcomes related to systemic or functional imbalance, specifically focusing on the physiological marker of high blood sugar. Research evaluated measurements of the levels of HbA1c, which is a key measure used in research for assessing average blood sugar levels over several months. Research also monitored the shorter-term metabolic marker, Fasting Plasma Glucose (FPG), during defined time intervals.

---

Long-Term Studies and Durability of Follow-Up

The follow-up durations for the primary efficacy trials were generally limited, with initial randomized comparative phases often spanning approximately 10 to 12 months. To extend this period of observation, researchers utilized open-label extension studies that evaluate data beyond the primary short-term trial periods. These extensions generated data, with some observation periods reaching up to two years.

---

Limitations and Areas of Research Uncertainty

The scientific literature highlights several limitations within the body of evidence. Systematic reviews examining the combined trial results have sometimes cited methodological heterogeneity (differences in study design and execution) among the included randomized trials, suggesting that evidence quality varies across studies.

A key limitation is that the original efficacy trials were primarily designed to study changes in blood sugar biomarkers. Data concerning long-term effects are not fully established, particularly concerning complex outcomes like major cardiovascular events, as those studies were generally not powered to evaluate those specific endpoints. This means that evidence highlights what is known—and what is still uncertain—about the drug's properties beyond short-term glucose changes.

Key Studies & References Intensive Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes (The ADVANCE Collaborative Group)

Common questions about Gliclada 60 mg (FAQ)

Q: Is Gliclada 60 mg the same as Diamicron MR?

Gliclada 60 mg contains the active substance Gliclazide. Diamicron MR is another medicine that also contains the same active substance in a Modified-Release formulation. These products contain the same active substance, Gliclazide Modified-Release.

Q: Can taking Gliclada make you feel dizzy or lightheaded?

Yes, regulatory documents list dizziness as an uncommon side effect, meaning it affects a small number of users. Dizziness and lightheadedness can also be key signs of hypoglycaemia (low blood sugar), which is a common side effect of this medicine.

Q: Is weight gain a common side effect of Gliclada 60 mg?

Weight gain is listed in official regulatory documents as an uncommon side effect of this medicine. An uncommon side effect is one that is reported to affect 1 to 10 users in every 1,000.

Q: What are the risks of taking Gliclada with NSAIDs (like ibuprofen)?

According to official product information, Non-Steroidal Anti-Inflammatory Agents (NSAIDs) may increase the blood sugar-lowering effect of Gliclada. This additive effect may increase the risk of hypoglycaemia (low blood sugar) if the two are used together.

Q: Does alcohol consumption affect how Gliclada works or increase side effects?

The consumption of alcohol is not recommended while taking Gliclada. Alcohol may potentiate the blood sugar-reducing action and also carries a risk of causing a disulfiram-like reaction.

Q: Are there specific warnings for people with liver issues when taking this medicine?

This medicine is contraindicated—meaning it should not be taken—by patients with severe liver (hepatic) impairment. It should be used with caution in patients with less severe liver issues, as this condition can increase the risk of hypoglycaemia.

Q: How long does the effect of Gliclada 60 mg typically last?

Gliclada 60 mg is a Modified-Release formulation designed to deliver the medicine slowly over an extended period. Because of this sustained-release delivery, the medicine is typically prescribed for once-daily administration, and is designed to support a sustained therapeutic effect throughout the day.

Q: Is it normal to have sweating or trembling while adjusting to Gliclada?

Sweating and trembling are two of the classical signs of hypoglycaemia (low blood sugar). Hypoglycaemia is listed as a common side effect of this medicine.

Q: What are the signs of low blood sugar (hypoglycemia) caused by Gliclada?

Signs of hypoglycaemia may include a headache, hunger, nausea, sweating, trembling, dizziness, sleepiness, and confusion. These symptoms are typically associated with low blood sugar.

Q: How often do people usually need blood tests when starting Gliclada?

Dose adjustments are made based on the patient's metabolic response (how well the sugar levels are controlled). Doses may be adjusted in increments after observing the metabolic response over a period of at least one month.

Q: What should I keep an eye out for when starting Gliclada 60 mg?

A primary area of focus when starting the medicine is the risk of hypoglycaemia (low blood sugar), particularly when starting the medicine or during dose changes. You should also be aware of the uncommon potential for gastrointestinal disturbances, such as nausea or abdominal pain.

Q: Does Gliclada 60 mg cause photosensitivity (increased sensitivity to the sun)?

Official regulatory documents list photosensitivity reactions as a rare side effect. This means there have been isolated reports of increased sensitivity to sunlight when taking the medication.

Q: Is Gliclada a generic or brand-name drug?

Gliclada is a brand name for a medicine that contains the active ingredient gliclazide. Gliclazide is the generic name for the compound that lowers blood sugar.

Q: Will Gliclada help me manage my HbA1c levels?

Yes, the primary function of Gliclada is to lower blood sugar levels. Research evidence has evaluated its ability to improve the long-term glucose biomarker known as Glycated Hemoglobin (HbA1c).

Q: Does Gliclada 60 mg interact with herbal supplements like St. John's Wort?

Official product information states that St. John's Wort (Hypericum perforatum) may reduce the concentration of Gliclada in the blood. This reduction may cause the medicine to be less effective at controlling blood sugar.

Q: What happens in the body when Gliclada causes hypoglycemia?

Gliclada is an insulin secretagogue, meaning it stimulates the pancreas to release insulin. Hypoglycaemia occurs if the blood sugar levels fall too low as a result of the medicine causing the release of too much insulin.

Q: Is it typical to feel slightly tired when first starting this drug?

Regulatory documents list tiredness or fatigue as potential symptoms of hypoglycaemia. Since low blood sugar is a common side effect, this feeling may occur while your body adjusts to the medicine.

Q: Are there any known long-term cardiovascular effects associated with Gliclada?

Regulatory documentation notes that while the medicine is intended to manage the risks of diabetes, the primary clinical trials were typically not powered to evaluate major cardiovascular events as their main study outcome.

Q: Can I drive or operate machinery safely while taking Gliclada 60 mg?

Your ability to concentrate or react may be impaired if your blood sugar is too low (hypoglycaemia) or too high (hyperglycaemia). For this reason, official guidance recommends awareness of the signs of hypoglycaemia before driving or operating machinery.

Storage and Disposal Requirements for Gliclada 60 mg

Storage Conditions

Gliclada 60 mg (Gliclazide modified-release tablets) must be stored according to official regulatory labeling to ensure product integrity.

• Temperature: While no special storage temperature is universally required, some labeling specifies storage at a temperature not exceeding 25°C. The medicine must not freeze.
• Protection: It is mandatory to store the product in a manner that provides protection from moisture. The container must be kept tightly closed to achieve this protection.
• Child Safety: The medication must be kept out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Gliclada 60 mg must be handled responsibly to protect the environment.

• Disposal Rule: All unused or waste medicinal product must be disposed of in accordance with local requirements.
• Prohibition: Do not throw away this medicine via wastewater or household waste. Consult a pharmacist for guidance on returning expired or unneeded medicine.